Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Asset Writedowns and Impairment (2019 - 2025)

Biodesix's Asset Writedowns and Impairment history spans 7 years, with the latest figure at -$57000.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 49.56% year-over-year to -$57000.0; the TTM value through Dec 2025 reached $49000.0, up 228.95%, while the annual FY2025 figure was $49000.0, 122.73% up from the prior year.
  • Asset Writedowns and Impairment reached -$57000.0 in Q4 2025 per BDSX's latest filing, down from $7000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $379000.0 in Q1 2022 to a low of -$719000.0 in Q4 2022.
  • Average Asset Writedowns and Impairment over 5 years is $15176.5, with a median of $26000.0 recorded in 2025.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 6533.33% in 2021, then crashed 272.54% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$193000.0 in 2021, then plummeted by 272.54% to -$719000.0 in 2022, then skyrocketed by 58.14% to -$301000.0 in 2023, then surged by 62.46% to -$113000.0 in 2024, then soared by 49.56% to -$57000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Asset Writedowns and Impairment are -$57000.0 (Q4 2025), $7000.0 (Q3 2025), and $26000.0 (Q2 2025).